Difference between revisions of "P40"
Jump to navigation
Jump to search
| Line 19: | Line 19: | ||
==General== | ==General== | ||
*Considered superior to [[p63]] as it is more [[specificity|specific]].<ref name=pmid22056955>{{Cite journal | last1 = Bishop | first1 = JA. | last2 = Teruya-Feldstein | first2 = J. | last3 = Westra | first3 = WH. | last4 = Pelosi | first4 = G. | last5 = Travis | first5 = WD. | last6 = Rekhtman | first6 = N. | title = p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. | journal = Mod Pathol | volume = 25 | issue = 3 | pages = 405-15 | month = Mar | year = 2012 | doi = 10.1038/modpathol.2011.173 | PMID = 22056955 }}</ref><ref name=pmid25263848>{{Cite journal | last1 = Alomari | first1 = AK. | last2 = Glusac | first2 = EJ. | last3 = McNiff | first3 = JM. | title = p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. | journal = J Cutan Pathol | volume = 41 | issue = 11 | pages = 839-45 | month = Nov | year = 2014 | doi = 10.1111/cup.12388 | PMID = 25263848 }}</ref> | *Considered superior to [[p63]] as it is more [[specificity|specific]].<ref name=pmid22056955>{{Cite journal | last1 = Bishop | first1 = JA. | last2 = Teruya-Feldstein | first2 = J. | last3 = Westra | first3 = WH. | last4 = Pelosi | first4 = G. | last5 = Travis | first5 = WD. | last6 = Rekhtman | first6 = N. | title = p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. | journal = Mod Pathol | volume = 25 | issue = 3 | pages = 405-15 | month = Mar | year = 2012 | doi = 10.1038/modpathol.2011.173 | PMID = 22056955 }}</ref><ref name=pmid25263848>{{Cite journal | last1 = Alomari | first1 = AK. | last2 = Glusac | first2 = EJ. | last3 = McNiff | first3 = JM. | title = p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. | journal = J Cutan Pathol | volume = 41 | issue = 11 | pages = 839-45 | month = Nov | year = 2014 | doi = 10.1111/cup.12388 | PMID = 25263848 }}</ref> | ||
**p63 stains a significant number of adenocarcinoma. | **p63 stains a significant number of [[adenocarcinoma]]s. | ||
==Staining== | ==Staining== | ||
Revision as of 17:38, 20 December 2016
| P40 | |
|---|---|
| Immunostain in short | |
| Similar stains | p63 |
| Use | lung (adenocarcinoma vs. squamous) |
| Normal staining pattern | nuclear staining |
| Positive | squamous cell carcinoma, urothelial carcinoma |
| Negative | prostate carcinoma, most lung adenocarcinoma, most breast carcinoma |
p40 an immunostain that is both sensitive and specific for squamous cell carcinoma. Like other "p" immunostains (e.g. p16, p63), it is a nuclear stain.
General
- Considered superior to p63 as it is more specific.[1][2]
- p63 stains a significant number of adenocarcinomas.
Staining
Positive
Negative
- Lung adenocarcinoma.
- Breast carcinoma.
- CK5 +ve breast carcinomas are typically p40 positive.[4]
- Prostate carcinoma.[5]
See also
- p63.
References
- ↑ Bishop, JA.; Teruya-Feldstein, J.; Westra, WH.; Pelosi, G.; Travis, WD.; Rekhtman, N. (Mar 2012). "p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.". Mod Pathol 25 (3): 405-15. doi:10.1038/modpathol.2011.173. PMID 22056955.
- ↑ Alomari, AK.; Glusac, EJ.; McNiff, JM. (Nov 2014). "p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma.". J Cutan Pathol 41 (11): 839-45. doi:10.1111/cup.12388. PMID 25263848.
- ↑ Brandler, TC.; Aziz, MS.; Rosen, LM.; Bhuiya, TA.; Yaskiv, O. (Jun 2014). "Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens.". Cancer Cytopathol 122 (6): 468-73. doi:10.1002/cncy.21424. PMID 24711443.
- ↑ Kővári, B.; Szász, AM.; Kulka, J.; Marušić, Z.; Šarčević, B.; Tiszlavicz, L.; Cserni, G. (Sep 2015). "Evaluation of p40 as a Myoepithelial Marker in Different Breast Lesions.". Pathobiology 82 (3-4): 166-71. doi:10.1159/000375127. PMID 26330357.
- ↑ Brustmann, H. (2015). "p40 as a Basal Cell Marker in the Diagnosis of Prostate Glandular Proliferations: A Comparative Immunohistochemical Study with 34betaE12.". Patholog Res Int 2015: 897927. doi:10.1155/2015/897927. PMID 25852959.